肿瘤电场治疗对新诊断胶质母细胞瘤患者健康相关生活质量的影响:随机临床试验二次分析
该二次分析基于EF-14随机临床试验,比较肿瘤电场治疗(TTFields)联合替莫唑胺与单用替莫唑胺在695例胶质母细胞瘤患者中的健康相关生活质量(HRQoL)。结果显示,除皮肤瘙痒外,两组HRQoL无显著差异;TTFields组在全局健康、躯体功能、情绪功能、疼痛和下肢无力等领域的无恶化生存期显著延长。
要点
- TTFields联合替莫唑胺未对HRQoL产生负面影响,仅皮肤瘙痒更常见。
- TTFields组全局健康、躯体功能、情绪功能、疼痛和下肢无力的无恶化生存期显著延长。
- 至恶化时间除皮肤瘙痒(TTFields更差)和疼痛(TTFields改善)外无显著差异。
核心结论
- 在胶质母细胞瘤患者中,标准替莫唑胺治疗基础上加用TTFields可改善生存,且除皮肤瘙痒外不负面影响HRQoL。
研究设计与样本
- EF-14 phase 3随机临床试验的二次分析,纳入695例完成放化疗的胶质母细胞瘤患者,按2:1随机接受TTFields联合替莫唑胺或单用替莫唑胺。
- 研究于2009年7月至2014年11月进行,随访至2016年12月。
- 主要终点为无进展生存期;HRQoL为预设次要终点,基线及每3个月用问卷评估。
主要发现
- 639例(91.9%)完成基线HRQoL问卷,其中437例(68.4%)为男性,平均年龄54.8(SD 11.5)岁。
- 除皮肤瘙痒外,两治疗组HRQoL无显著差异。
- TTFields组无恶化生存期显著更长:全局健康4.8 vs 3.3个月(P < .01);躯体功能5.1 vs 3.7个月(P < .01);情绪功能5.3 vs 3.9个月(P < .01);疼痛5.6 vs 3.6个月(P < .01);下肢无力5.6 vs 3.9个月(P < .01)。
- 至恶化时间除皮肤瘙痒(TTFields更差,8.2 vs 14.4个月,P < .001)和疼痛(TTFields改善,13.4 vs 12.1个月,P < .01)外无显著差异。
- 角色、社交和躯体功能未受TTFields影响。
关键数值与推荐
- 替莫唑胺剂量为150至200 mg/m2/d,每28天周期中给药5天。
- TTFields通过置于剃发头皮的4个换能器阵列连续 delivery,连接便携医疗设备。
临床怎么用
- 对于完成放化疗的新诊断胶质母细胞瘤患者,TTFields联合替莫唑胺是可考虑的治疗选择,其生存获益不伴随HRQoL的总体下降。
- 应预期并管理TTFields相关的皮肤瘙痒,但疼痛可能改善。
局限性
- 本文为二次分析,HRQoL为次要终点。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). OBJECTIVE: To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy. Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide alone. The study was conducted from July 2009 until November 2014, and patients were followed up through December 2016. INTERVENTIONS: Temozolomide, 150 to 200 mg/m2/d, was given for 5 days during each 28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed on the shaved scalp of patients and were connected to a portable medical device. MAIN OUTCOMES AND MEASURES: Primary study end point was progression-free survival; HRQoL was a predefined secondary end point, measured with questionnaires at baseline and every 3 months thereafter. Mean changes from baseline scores were evaluated, as well as scores over time. Deterioration-free survival and time to deterioration were assessed for each of 9 preselected scales and items. RESULTS: Of the 695 patients in the study, 639 (91.9%) completed the baseline HRQoL questionnaire. Of these patients, 437 (68.4%) were men; mean (SD) age, 54.8 (11.5) years. Health-related quality of life did not differ significantly between treatment arms except for itchy skin. Deterioration-free survival was significantly longer with TTFields for global health (4.8 vs 3.3 months; P < .01); physical (5.1 vs 3.7 months; P < .01) and emotional functioning (5.3 vs 3.9 months; P < .01); pain (5.6 vs 3.6 months; P < .01); and leg weakness (5.6 vs 3.9 months; P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting the influence of treatment, did not differ significantly except for itchy skin (TTFields worse; 8.2 vs 14.4 months; P < .001) and pain (TTFields improved; 13.4 vs 12.1 months; P < .01). Role, social, and physical functioning were not affected by TTFields. CONCLUSIONS AND RELEVANCE: The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00916409.
引用
- Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29392280. doi:10.1001/jamaoncol.2017.5082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。